CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on developing novel peptidomimetic agents that specifically inhibit the Wnt signaling pathway by targeting the beta-catenin protein. This approach aims to create targeted therapies for colorectal cancer, particularly for cases that are resistant to conventional treatments.
With more than 1.9 million new cases and 935,000 related deaths in 2020, colorectal cancer (CRC) is the third most common cancer in men and the second in women.
While surgery is the main treatment option for lower grade CRC, patients with unresectable lesions are treated with chemotherapy.
Related therapies are associated with severe drawbacks, such as systemic toxicity, low response rate, and unpredictable resistance.
Molecular targeted therapies have emerged as a promising strategy to specific…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
